Lamotrigine

Matsuo, Fumisuke

doi:10.1111/j.1528-1157.1999.tb00917.x

Cited by 82 publications

(54 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A epilepsia refratária implica em grandes custos para os sistemas de saúde nacionais, conforme demonstrado por um estudo observacional realizado na Itália, que estimou o custo anual per capita situado entre 2.190,00 e 3.268,00 euros para o tratamento de adultos e crianças, respectivamente (BEGHI et al, 2004(BEGHI et al, , 2005 (PELLOCK, 1994;BURGEOSIS, 1998;MATSUO, 1999;BRODIE, 2001;BEYENBURG;BAVER;REUBER, 2004;FDA, 2005 Os parâmetros farmacocinéticos da LTG estão apresentados na Tabela 1.…”

Section: Acesso Aos Medicamentos Para Tratamento Da Epilepsia No Brasilunclassified

Epilepsia Refratária e Lamotrigina: Monitorização terapêutica e resposta clínica em pacientes ambulatoriais

Baldoni¹

View full text Add to dashboard Cite

Section: Acesso Aos Medicamentos Para Tratamento Da Epilepsia No Brasilunclassified

Epilepsia Refratária e Lamotrigina: Monitorização terapêutica e resposta clínica em pacientes ambulatoriais

Baldoni¹

View full text Add to dashboard Cite

“…Lamotrigine (LTG), a triazine compound, was approved by the United States Food and Drug Administration in 1994 for use as an anticonvulsive drug for treating epileptic patients (Matsuo, 1999) (Supplemental Fig. 1).…”

Section: Introductionmentioning

confidence: 99%

“…There is an increasing body of evidence to suggest that LTG is an effective anticonvulsive drug for the treatment of different types of patients with epilepsy (Clemens et al, 2008). For instance, LTG effectively controls Lennox-Gastaut syndrome (Motte et al, 1997;Matsuo, 1999), juvenile myoclonic epilepsy (Buchanan, 1996), Angelman syndrome (Dion et al, 2007), primary generalized tonic-clonic seizures (Trevathan et al, 2006), and patients with partial seizures (Labiner et al, 2009). The evidence indicates that LTG may exert its antiepileptic effect by inhibiting sodium channels (Cheung et al, 1992;Zona and Avoli, 1997).…”

Section: Introductionmentioning

confidence: 99%

The Anticonvulsive Drug Lamotrigine Blocks Neuronal α4β2 Nicotinic Acetylcholine Receptors

Zheng

Yang²,

Liu³

et al. 2010

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Lamotrigine (LTG), an anticonvulsive drug, is often used for the treatment of a variety of epilepsies. In addition to block of sodium channels, LTG may act on other targets to exert its antiepileptic effect. In the present study, we evaluated the effects of LTG on neuronal nicotinic acetylcholine receptors (nAChRs) using the patch-clamp technique on human ␣4␤2-nAChRs heterologously expressed in the SH-EP1 cell line and on native ␣4␤2-nAChRs in dopaminergic (DA) neurons in rat ventral tegmental area (VTA). In SH-EP1 cells, LTG diminished the peak and steady-state components of the inward ␣4␤2-nAChR-mediated currents. This effect exhibited concentration-, voltage-and use-dependent behavior. Nicotine doseresponse curves showed that in the presence of LTG, the nicotine-induced maximal current was reduced, suggesting a noncompetitive inhibition. These findings suggest that LTG inhibits human neuronal ␣4␤2-nAChR function through an openchannel blocking mechanism. LTG-induced inhibition in ␣4␤2-nAChRs was more profound when preceded by a 2-min pretreatment, after which the nicotine-induced current was reduced even without coapplication of LTG, suggesting that LTG is also able to inhibit ␣4␤2-nAChRs without channel activation. In freshly dissociated VTA DA neurons, LTG inhibited ␣4␤2-nAChR-mediated currents but did not affect glutamate-or GABA-induced currents, indicating that LTG selectively inhibits nAChR function. Collectively, our data suggest that the neuronal ␣4␤2-nAChR is likely an important target for mediating the anticonvulsive effect of LTG and the blockade of ␣4␤2-nAChR possibly underlying the mechanism through which LTG effectively controls some types of epilepsy, such as autosomal dominant nocturnal frontal lobe epilepsy or juvenile myoclonic epilepsy.

show abstract

“…2,3 Its mechanism of action is determined by its action blocking Na+ channels 4 and a possible action on NMDA receptors. 4,5 The pharmacokinetic profile of LTG demonstrates good absorption after oral administration, a linear relation between dose and plasma concentrations, ~55% protein binding, and an elimination half-life of 25-30 h with monotherapy.…”

Section: Introductionmentioning

confidence: 99%

Late side-effects of valproate and lamotrigine

Moreira

Thomé‐Souza

Valente

2007

J. epilepsy clin. neurophysiol.

View full text Add to dashboard Cite

Lamotrigine (LTG) is a generally well-tolerated antiepileptic drug with broad-spectrum efficacy in several forms of partial and generalized epilepsy. Adverse effects of lamotrigine are usually associated with introduction and titration. This risk increases in children and in the co-medication with valproate. Herein, we report four patients with late adverse-effects, under the co-medication valproate and LTG, not related to drug introduction or titration. This study demonstrates that late side-effects without apparent etiology in children, adolescents and adults in chronic use of LTG, especially when associated to VPA, led to a diagnostic investigation, sometimes invasive. It must be emphasized that, due to the excellent seizure control, the authors opted for drug decrease instead of drug withdrawal, as previously done. Studies on late adverse effects are scarce, but physicians must be aware of these risks.Key words: lamotrigine, side-effects, epilepsy, anti-epileptic drugs. RESUMOEfeitos adversos tardios no uso de valproate e lamotrigina Lamotrigina (LTG) é uma droga antiepiléptica bem tolerada com eficácia em diferentes formas de epilepsia, parcial e generalizada. Os efeitos adversos da lamotrigina estão freqüentemente associados com a sua introdução e a sua titulação. Este risco encontra-se aumentado em crianças e quando a LTG é usada em associação com o valproato. Nós relatamos quatro pacientes que apresentaram efeitos adversos tardios com a co-administração de LTG e valproato, não relacionados à introdução ou o escalonamento das drogas antiepilépticas. Este estudo demonstra que efeitos adversos tardios sem etiologia aparente nas crianças, adolescentes e adultos em uso crônico de LTG, especialmente quando associados ao valproato, levou à investigação diagnóstica, por vezes invasiva. Os autores enfatizam que, devido ao bom controle de crises, os autores optaram pela redução da dose ao invés da suspensão da medicação, como previamente realizado. Embora os estudos sobre efeitos adversos tardios das drogas antiepilépticas sejam escassos, os clínicos devem estar cientes deste risco.Unitermos: lamotrigine, efeitos adversos, epilepsia, drogas antiepilépticas.

show abstract

Lamotrigine

Cited by 82 publications

References 50 publications

Epilepsia Refratária e Lamotrigina: Monitorização terapêutica e resposta clínica em pacientes ambulatoriais

Epilepsia Refratária e Lamotrigina: Monitorização terapêutica e resposta clínica em pacientes ambulatoriais

The Anticonvulsive Drug Lamotrigine Blocks Neuronal α4β2 Nicotinic Acetylcholine Receptors

Late side-effects of valproate and lamotrigine

Contact Info

Product

Resources

About